Skip to main content
SpringerLink
Log in

Hormone Therapy in Normal Postmenopausal Women and After Treatment for Endometrial Cancer

  • Chapter
Book cover Uterine Cancer

  • 1174 Accesses

Abstract

About 20–25 % of women with endometrial carcinomas are diagnosed premenopausaly [1]. Hysterectomy and bilateral salpingo-oophorectomy the obligatory operative therapy, results in surgically induced menopause. The abrupt loss of estrogen gives rise to deficiency symptoms, mainly hot flushes, sleep disorders, and depressive mood, reducing quality of life. Hormone therapy (HT) has been used for decades to improve quality of life of menopausal women by reducing menopausal symptoms. The role of hormone therapy in women with endometrial cancer and risk of endometrial cancer in women on hormones will be discussed in this chapter.

We keep dreaming of a future, a future with a long and healthy life…

Not lived in the shadow of cancer but in healthy light….

-Patrick Swayze

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mueck AO, Seeger H. Hormone therapy after endometrial cancer. Endocr Relat Cancer. 2004;11:305–14.

    Article  CAS  PubMed  Google Scholar 

  2. Crosignani PG. Effects of hormone replacement therapy. Int J Fertil. 1992;37 Suppl 2:98–103.

    PubMed  Google Scholar 

  3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.

    Article  CAS  PubMed  Google Scholar 

  4. Beral V. Breast cancer and hormone- therapy in the Million Women Study. Lancet. 2003;362(9382):419–27.

    Article  CAS  PubMed  Google Scholar 

  5. Langer RD, Manson JE, Allison MA. Have we come full circle – or moved forward? The Women’s Health Initiative 10 years on. Climacteric. 2012;15(3):206–12.

    Article  CAS  PubMed  Google Scholar 

  6. Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc. 2003;9:27–31.

    Article  PubMed  Google Scholar 

  7. Romer T, Mueck AO. Endometrium und hormone substitution. Stuttgart: Georg Thieme Verlag; 1998.

    Google Scholar 

  8. Seeger H, Wallwiener D, Mueck AO. Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells. J Br Menopause Soc. 2003;9:36–9.

    Article  PubMed  Google Scholar 

  9. Jane FM, Davis SR. A practitioner’s toolkit for managing the menopause. Climacteric. 2014;17:1–16.

    Article  Google Scholar 

  10. Sturdee DW. Are progestins really necessary as part of a combined HRT regimen? Climacteric. 2013;16 Suppl 1:79–84.

    Article  CAS  PubMed  Google Scholar 

  11. Clavel-Chapelon F, van Liere MJ, Giubout C, Niravong MY, Goulard H, Le Corre C, et al. E3N, a French cohort study on cancer risk factors. E3N group. Eur J Cancer Prev. 1997;6(5):473–8.

    Article  CAS  PubMed  Google Scholar 

  12. Panay N, Hamoda H, Arya R, Savvas M. British Menopause Society & Women’s Health Concern recommendations on hormone therapy. Menopause Int. 2013;19(2):59–68.

    PubMed  Google Scholar 

  13. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin study follow-up (HERS II). JAMA. 2002;288:58–66.

    Article  CAS  PubMed  Google Scholar 

  14. Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol. 2014;142:83–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Feeley K, Wells M. Hormone therapy and the endometrium. J Clin Pathol. 2001;54(6):435–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin therapy and endometrial cancer. J Natl Cancer Inst. 1997;89:1110–6.

    Article  CAS  PubMed  Google Scholar 

  17. Lacey JV, Leitzmann MF, Chang SC, et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health study cohort. Cancer. 2007;109:1303–11.

    Article  CAS  PubMed  Google Scholar 

  18. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen with and without progestins. J Natl Cancer Inst. 1999;91:1131–7.

    Article  CAS  PubMed  Google Scholar 

  19. Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer. 2011;128(7):1644–51.

    Article  CAS  PubMed  Google Scholar 

  20. Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:475–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Lacey JV, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14:172–31.

    Article  Google Scholar 

  22. Grady D, Gebretsadik T, Kerlikowski K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304–15.

    Article  CAS  PubMed  Google Scholar 

  23. Hill DA, Weiss NS, Beresford SAA, Voigt LF, Daling JR, Stanford JL, Self S. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol. 2000;183:1456–61.

    Article  CAS  PubMed  Google Scholar 

  24. Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10:253–60.

    Article  CAS  PubMed  Google Scholar 

  25. Lee SJ, Yeo SG, Kang SB, Park DC. Attitudes and practices of Korean gynecologists forwards hormone replacement therapy inendometrial cancer survivors. Eur J Gynaecol Oncol. 2013;34(6):513–7.

    CAS  PubMed  Google Scholar 

  26. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Uterine neoplasms V.1.2010. Fort Washington: NCCN; 2010.

    Google Scholar 

  27. de Villiers TJ, Gass MLS, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global consensus statement on menopausal hormone therapy. Climacteric. 2013;16:203–4.

    Article  PubMed  Google Scholar 

  28. The North American Menopause Society. The hormone therapy position statement of the North American menopause society. Menopause. 2012;19(3):257–71.

    Google Scholar 

  29. American College of Obstetricians and Gynecologists (ACOG). Hormone replacement therapy in women treated for endometrial cancer. Committee opinion 235. Int J Gynecol Obstet. 2001;73:283–4.

    Article  Google Scholar 

  30. Creasman WT. HRT and women who have had breast or endometrial cancer. J Epidemiol Biostat. 1999;4:217–25.

    CAS  PubMed  Google Scholar 

  31. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol. 1990;36:189–91.

    Article  CAS  PubMed  Google Scholar 

  32. Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol. 1996;175:1195–200.

    Article  CAS  PubMed  Google Scholar 

  33. Suriano KA, McHale M, McLaren CE, Li KF, Re A, DiSaja PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol. 2001;97:955–60.

    Article  Google Scholar 

  34. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky T. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998;82:1784–8.

    Article  CAS  PubMed  Google Scholar 

  35. Farish E, Barnes JF, O’Donoghue F, Fletcher CD, Ekevall K, Hart DM. The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric. 2000;3:125–34.

    Article  CAS  PubMed  Google Scholar 

  36. Mirkin S, Archer DF, Taylor HS, Pickar JH, Komm BS. Differential effects of menopausal therapies on the endometrium. Menopause. 2014;21(8):899–908. [Epub ahead of print].

    Article  PubMed  Google Scholar 

  37. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007;92(3):911–8.

    Article  CAS  PubMed  Google Scholar 

  38. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), the physiological and a highly efficient treatment of vaginal atrophy. Menopause. 2009;16(5):907–12.

    Article  PubMed  Google Scholar 

  39. Kulak Jr J, Ferriani RA, Komm BS, Taylor HS. Tissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cells. Reprod Sci. 2013;20(2):129–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Mueck AO, Seeger H, Haasis R, Gohlke-Ba¨rwolf C, Schieber M, Schuchert A, Meinertz T. Effect of oral vs. transdermal estradiol on cGMP during exercise in women with coronary artery disease—randomized, double-blind, placebo-controlled cross over study. Circulation. 1999;100(18):1386.insert last page.

    Google Scholar 

  41. Guttuso T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomised controlled trial. Obstet Gynecol. 2003;101:337–45.

    Article  CAS  PubMed  Google Scholar 

  42. Johnson EB, Muto MG, Yanushpolsky EH, Mutter GL. Phytoestrogen supplementation and endometrial cancer. Obstet Gynecol. 2001;98:947–50.

    Article  CAS  PubMed  Google Scholar 

  43. Quaas AM, Kono N, Mack WJ, Hodis HN, Felix JC, Paulson RJ, Shoupe D. Effect of isoflavone soy protein supplementation n endometrial thickness, hyperplasia, andendometrial cancer risk in postmenopausal women: a randomized controlled trial. Menopause. 2013;20(8):840–4.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Graziottin A. Loss of libido in the postmenopause. Menopausal Med. 2000;8(1):9–12.

    Google Scholar 

  45. Chughtai B, Levin R, De E. Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin. Clin Interv Aging. 2008;3(3):503–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  46. Van Der Laak JA, De Bie LM, De Leeuw H, De Wilde PC, Hanselaar AG. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol. 2002;55:446–51.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics & Gynecology, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India

    Nilanchali Singh MD, DNB, Shalini Rajaram MD, FAMS & Neerja Goel MD, FAMS, FIMSA, FICOG, FFGSI

Authors
  1. Nilanchali Singh MD, DNB
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shalini Rajaram MD, FAMS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neerja Goel MD, FAMS, FIMSA, FICOG, FFGSI
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nilanchali Singh MD, DNB .

Editor information

Editors and Affiliations

  1. Obstetrics and Gynecology, University College of Medical Sciences, New Delhi, India

    Shalini Rajaram

  2. Surgical &Gynec Oncology, Lakeshore & Welcare Hospitals, Kochi, Kerala, India

    Chitrathara K

  3. Gynec Onclogy, Tata Memorial Hospital, Mumbai, India

    Amita Maheshwari

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer India

About this chapter

Cite this chapter

Singh, N., Rajaram, S., Goel, N. (2015). Hormone Therapy in Normal Postmenopausal Women and After Treatment for Endometrial Cancer. In: Rajaram, S., K, C., Maheshwari, A. (eds) Uterine Cancer. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1892-0_40

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-1892-0_40

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-1891-3

  • Online ISBN: 978-81-322-1892-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation